Cocrystal Pharma Reports 2017 Financial Results and Provides Corporate Overview and Business Outlook
March 22, 2018 07:05 ET
|
Cocrystal Pharma, Inc.
–Company successfully completes uplisting to the NASDAQ Capital Market – –Company positioned to achieve clinical and regulatory milestones over the course of 2018– ATLANTA, GA and BOTHELL, WA, March...
Cocrystal Pharma Announces Uplist to The Nasdaq Capital Market
March 12, 2018 08:30 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, March 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and...
Cocrystal Pharma Provides Update on Reverse Stock Split
January 23, 2018 16:30 ET
|
Cocrystal Pharma, Inc.
- Reverse stock split to be effective on Wednesday, January 24, 2018 on split-adjusted basis under trading symbol “COCPD” - ATLANTA, GA and BOTHELL, WA, Jan. 23, 2018 (GLOBE NEWSWIRE) --...
Cocrystal Pharma Announces 1-for-30 Reverse Stock Split
January 23, 2018 09:15 ET
|
Cocrystal Pharma, Inc.
– Reverse stock split positions Company to uplist to the NASDAQ Capital Market in Q1 2018 – – Company expects to commence Phase 2a study in Q1 2018 for lead program, CC-31244, for the treatment of...
Cocrystal Pharma Announces Filing 2017 Third Quarter Financial Statements and Provides Company Update
November 08, 2017 17:30 ET
|
Cocrystal Pharma, Inc.
ATLANTA, GA and BOTHELL, WA, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, today announced...